Perimeter Medical Imaging AI Launches OCT-Tissue Registry to Advance Surgical Imaging and AI-Driven Cancer Care

Perimeter Medical Imaging AI Launches OCT-Tissue Registry to Advance AI and Imaging Technology

Perimeter Medical Imaging AI has introduced the OCT-Tissue Surveillance Registry, a new database designed to collect thousands of images and data from surgical procedures using the company’s advanced imaging technology. This initiative aims to accelerate product development and refine the AI deep-learning models that support Perimeter’s imaging systems.

The company’s S-Series OCT technology offers surgeons real-time, ultra-high resolution visualization of tissue specimens during surgery. Building on this, the investigational B-Series OCT with ImgAssist AI 2.0 integrates AI to assist surgeons in identifying suspicious tissue during breast-conserving surgeries. This next-generation system is currently under FDA review.

Real-World Data to Enhance AI Model Training

Dr. Jennifer Tittensor, a general surgeon who has used Perimeter’s OCT technology in over 120 surgeries, highlighted its value in assessing surgical margins instantly. According to Dr. Tittensor, this technology supports decision-making during surgery by helping to determine if more tissue needs to be removed, potentially reducing the need for follow-up operations.

The OCT-Tissue Registry is key to gathering diverse patient data, including images from a wide range of demographics and tissue types. Collecting this varied dataset is essential for improving AI algorithm accuracy, ultimately enabling more personalized patient care and better surgical outcomes.

How the Registry Supports Product Development

• Enables continuous improvement of AI algorithms by feeding them real-world images and clinical data.
• Allows surgeons to contribute retrospective data and track patient outcomes over time.
• Supports the refinement of investigational B-Series OCT technology with ImgAssist AI 2.0.

Perimeter’s CEO, Adrian Mendes, emphasized the importance of collaboration with surgeons to collect high-quality data from a broad patient population. The goal is to train AI models that can detect subtle patterns across diverse tissue types, reducing the frequency of second surgeries due to residual cancer.

Current Status and Challenges

While the S-Series OCT system is FDA-cleared for imaging excised tissue, the B-Series OCT with ImgAssist AI 2.0 remains under FDA premarket approval review. Its success will depend on surgeons’ voluntary participation and data contributions to the registry.

Developing AI for medical use demands large, diverse datasets reflecting multiple patient characteristics like age, ethnicity, and tissue density. Perimeter’s AI models have been trained on millions of proprietary OCT images, but real-world data from the registry will enhance these models further.

About Perimeter Medical Imaging AI

Based in Toronto and Dallas, Perimeter Medical Imaging AI (TSXV: PINK) (OTCQX: PYNKF) focuses on delivering real-time, ultra-high-resolution imaging tools to improve cancer surgery. Their FDA-cleared S-Series OCT system provides cross-sectional visualization of excised tissues at the cellular level.

The investigational B-Series OCT with ImgAssist AI, supported by a Cancer Prevention and Research Institute of Texas grant, offers 3D imaging combined with AI-assisted detection to identify suspicious tissue during breast cancer surgeries. Patient enrollment for pivotal clinical trials was completed in September 2024, with FDA submission expected in 2025.

Device Intended Uses and Regulatory Status

• S-Series OCT: Used as an imaging tool for evaluating excised human tissue microstructure in real-time. It has 510(k) clearance but is not FDA-evaluated specifically for breast tissue or margin assessment.
• B-Series OCT with ImgAssist AI 2.0: Intended as an adjunctive 3D imaging tool with AI detection of suspicious areas in breast cancer lumpectomy specimens. It is currently limited to investigational use under U.S. law and not available for sale.

For more information or to inquire about participation in the OCT-Tissue Registry, contact Perimeter Medical Imaging AI Clinical Affairs at clinical@perimetermed.com.

Professionals involved in product development can follow this initiative as an example of integrating real-world clinical data to enhance AI in medical devices. To explore AI courses relevant to healthcare and imaging technology, visit Complete AI Training.